Evaluating Efficacy of Antiseptic Mouth Rinses on Salivary SARS-CoV-2 Infectivity

评估抗菌漱口水对唾液 SARS-CoV-2 感染性的功效

• 批准号: 10354566
• 负责人: Laura Anne Jacox
• 金额: $ 15.55万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-10 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10354566
• 关键词: 2019-nCoV; Address; Adoption; Aerosols; Antibodies; Antibody Response; Antibody titer measurement; Antigenic Specificity; Biological Assay; COVID-19; COVID-19 pandemic; COVID-19 patient; Caring; Cessation of life; Cetylpyridinium Chloride; Chlorhexidine; Clinical Trials; Collaborations; Critical Illness; Data; Dental; Dentists; Development; Discipline; Disease; Ensure; Ethanol; Evaluation; FDA approved; Face; Faculty; Frontline worker; Generations; Goals; Head and neck structure; Health Personnel; Healthcare; Hydrogen Peroxide; Immune response; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologics; Infection; Inflammation; Inflammatory Response; Intervention; Investigation; Knowledge; Local Anti-Infective Agents; Maps; Measures; Mediator of activation protein; Methodology; Mouthwash; Occupational Exposure; Oral; Oral Characters; Oral cavity; Outcome; Outpatients; Patients; Population; Povidone-Iodine; Prognostic Marker; Property; Proteins; Protocols documentation; Public Health; Randomized Clinical Trials; Randomized Controlled Trials; Reporting; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 infection; Saliva; Salivary; Salivary Glands; Sampling; School Dentistry; Site; Social Environment; Technology; Time; Ultrasonics; Vaccines; Viral; Viral Load result; Virus Replication; Work; Workplace; anti-viral efficacy; biobank; chemokine; cohort; cytokine; diagnostic biomarker; efficacy evaluation; experience; health care settings; high risk; in vivo; infection risk; innovation; novel; novel diagnostics; pathogen; professional atmosphere; public health emergency; respiratory; saliva sample; social; socioeconomics; therapeutic biomarker; tool; translational impact; transmission process; viral transmission; virus envelope

ABSTRACT Evaluating the antiviral potential of widely available commercial antiseptic rinses on SARS-CoV-2 infectivity holds great potential for rapidly reducing viral transmission, particularly as novel strains emerge. Given that SARS- CoV-2 is transmitted primarily through aerosols and salivary and respiratory secretions, strategies to reduce viral burden is an attractive approach to mitigating spread; this is particularly true for dental and other healthcare settings which have high patient volumes, require work in close proximity to the head and neck, and generate procedural aerosols. Though studies have demonstrated that some antiseptic mouth rinses have antiviral properties against SARS-CoV-2 in vitro and other enveloped viruses in vivo, data are still emerging from recent randomized clinical trials (RCT), including ours at the Adams School of Dentistry, regarding whether antiseptic mouth rinses reduce SARS-CoV-2 in vivo. To address this gap in knowledge, we propose to determine whether mouth rinses containing ethanol, hydrogen peroxide, povidone-iodine, chlorhexidine, or cetylpyridinium chloride reduce SARS-CoV-2 viral load, replication and infectivity (Aim 1) and to characterize salivary inflammatory and antibody responses associated with early SARS-CoV-2 infection (Aim 2) using salivary samples derived from our recent COVID-19+ patient RCT. Altogether, the data generated from these aims will demonstrate whether antiseptic rinses reduce salivary SARS-CoV-2 viral load and infectivity, and will characterize the local inflammatory response to SARS-CoV-2 in the oral cavity with the ultimate goal of limiting viral spread. These studies will generate data to develop feasible, inexpensive, rapidly implementable protocols to mitigate the spread of SARS-CoV-2 and address this urgent public health need with broad translational impact. Our interdisciplinary team is uniquely qualified to conduct the proposed work as we have the innovative methodologies, BLS2+ facilities, SARS-CoV-2+ samples, and expertise to achieve our aims. This application includes collaboration between experienced and junior faculty across multiple disciplines to ensure the rigor and translatability of our findings.

抽象的 评估广泛使用的商业消毒冲洗液对 SARS-CoV-2 感染的抗病毒潜力 快速减少病毒传播的巨大潜力，特别是当新毒株出现时。鉴于非典—— CoV-2 主要通过气溶胶、唾液和呼吸道分泌物传播，减少病毒传播的策略 负担是减轻传播的一种有吸引力的方法；对于牙科和其他医疗保健尤其如此 病人数量较多的环境，需要在靠近头部和颈部的地方进行工作，并产生 程序性气溶胶。尽管研究表明一些抗菌漱口水具有抗病毒作用 体外对抗 SARS-CoV-2 和体内对抗其他包膜病毒的特性，最近的数据仍在不断涌现 随机临床试验 (RCT)，包括我们在亚当斯牙科学院进行的关于抗菌剂是否有效的随机临床试验 漱口水可减少体内 SARS-CoV-2。为了解决这一知识差距，我们建议确定是否 含有乙醇、过氧化氢、聚维酮碘、氯己定或氯化西吡啶的漱口水 减少 SARS-CoV-2 病毒载量、复制和感染性（目标 1）并表征唾液炎症和 使用来自以下来源的唾液样本进行与早期 SARS-CoV-2 感染相关的抗体反应（目标 2）： 我们最近的 COVID-19+ 患者随机对照试验。总而言之，从这些目标生成的数据将证明是否 消毒冲洗液可减少唾液 SARS-CoV-2 病毒载量和传染性，并将表征当地的情况 口腔中对 SARS-CoV-2 的炎症反应，最终目标是限制病毒传播。这些 研究将产生数据来制定可行、廉价、可快速实施的协议，以减轻 SARS-CoV-2 的传播并解决这一紧迫的公共卫生需求，具有广泛的转化影响。我们的 跨学科团队具有独特的资格来开展拟议的工作，因为我们拥有创新的 方法、BLS2+ 设施、SARS-CoV-2+ 样本以及实现我们目标的专业知识。这个应用程序 包括跨多个学科的经验丰富和初级教师之间的合作，以确保严谨和 我们的研究结果的可翻译性。